Safe Guanfacine Dosing
For ADHD treatment in children and adolescents (ages 6-17), start with 1 mg once daily at bedtime and titrate by 1 mg weekly as tolerated to a target dose range of 1-7 mg/day (or 0.05-0.12 mg/kg/day), with most patients responding adequately at 1-4 mg daily. 1, 2
Standard Dosing Guidelines
For ADHD (Children and Adolescents)
The 2024 American Journal of Obstetrics and Gynecology guidelines and 2022 Pharmacology & Therapeutics review provide consistent dosing recommendations 1, 2:
- Starting dose: 1 mg once daily (typically at bedtime)
- Titration: Increase by 1 mg per week based on response and tolerability
- Target range: 1-7 mg/day or 0.05-0.12 mg/kg/day
- Weight-based dosing: Approximately 0.1 mg/kg as a rule of thumb 2
- Available tablet strengths: 1,2,3, and 4 mg 2
A 2008 randomized controlled trial demonstrated efficacy at 2,3, and 4 mg daily doses, with the 4 mg dose showing the greatest effect (mean reduction of -18.87 points on ADHD Rating Scale IV versus -8.48 for placebo) 3. However, the 2023 meta-analysis of 12 RCTs with 2653 participants confirmed guanfacine's overall efficacy and safety profile across the therapeutic range 4.
For Hypertension (Adults)
The FDA-approved dosing for hypertension differs significantly 5:
- Starting dose: 1 mg daily at bedtime
- Titration: May increase to 2 mg after 3-4 weeks if needed
- Maximum recommended: 3 mg/day (doses above 3 mg significantly increase adverse reactions)
- Note: Most antihypertensive effect is seen at 1 mg 5
Multiple 1986 studies confirmed that 1 mg daily is the lowest safe and therapeutically effective dose for hypertension when combined with a diuretic 6, 7.
Important Safety Considerations
Common Adverse Effects
Approximately 80% of patients experience at least one treatment-emergent adverse event (compared to 66.5% with placebo) 4:
- Most common: Somnolence (38.6%), headache (20.5%), fatigue (15.2%) 4
- Cardiovascular: Hypotension, bradycardia (monitor blood pressure and heart rate) 2
- Other: Dry mouth, dizziness, irritability, insomnia, nightmares, abdominal pain 2, 8
Critical Warnings
Never abruptly discontinue guanfacine - taper gradually to avoid rebound hypertension, which can occur 2-4 days after sudden withdrawal 5. This is particularly important given guanfacine's longer half-life (approximately 17 hours, range 10-30 hours) 5.
Overdose Data
Pediatric exposure data from 2000-2016 (10,927 cases) showed 9:
- Median ingested dose: 0.11 mg/kg (range 0.004-7.8 mg/kg)
- Major effects were rare but occurred at doses as low as 0.05 mg/kg in young children
- Most common toxicity: drowsiness, bradycardia, hypotension
- Duration of effects typically >8 hours but ≤24 hours
- Any symptomatic pediatric patient should be observed in a healthcare facility for at least 24 hours 9
Special Populations
Pregnancy and Breastfeeding
Exercise caution - very limited safety data exists 1:
- Only one published study (30 patients with preeclampsia, all beyond first trimester) showed no congenital malformations but 20% low birth weight
- No published studies on guanfacine during breastfeeding
- Alternative agents are generally preferred 1
Adults with ADHD
Limited efficacy and safety data exist for adults with ADHD 1. Guanfacine is approved in Canada only for children and adolescents ages 6-17 1.
Clinical Pearls
- Once-daily dosing at bedtime minimizes somnolence 5
- Guanfacine is 10 times less potent than clonidine but has higher specificity for alpha-2A receptors, resulting in less sedation 2
- Primarily metabolized via CYP3A4 and excreted renally 2
- Consider as second-line therapy when stimulants are unsuitable, not tolerated, or ineffective 2
- Can be used as adjunctive therapy with stimulants (FDA-approved indication) 2, 8
- Therapeutic effects may take 2-4 weeks to fully manifest 2